NCT07219186View on ClinicalTrials.gov

Kava Aging and Mobility Study

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Old AdultsSleep QualityKavaMobility ImpairmentPhysical Activity and StressPhysical ImpairmentSedentary Lifestyle in Patients Over 70
Interventions
DRUG

AB-free kava

AB-free kava (75mg kavalactones per capsule, for a total of 225 mg/day)

OTHER

Placebo

Participants will consume microcrystalline cellulose in capsules identical to AB-free kava, which will be provided by Thorne Research. There are no active ingredients in the placebo capsules.

Trial Locations (2)

32610

Institute on Aging University of Florida, Gainesville

Institute on Aging Unversity of Florida, Gainesville

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Florida

OTHER

NCT07219186 - Kava Aging and Mobility Study | Biotech Hunter | Biotech Hunter